GanglioCombi™ MAG ELISA offers the possibility for the investigation of anti-Ganglioside antibodies as well as anti-MAG (myelin-associated glycoproteins) antibodies in the same approach. The Kit contains all 3 Enzyme labels: IgG/IgM-Mix, IgG and IgM that allows cost-effective algorithms including testing in 2 steps: (1st) Initial screening for antibodies with the IgM/IgG-mix followed by (2nd) separate re-testing of positive samples with IgG- and IgM-enzyme label to identify the underlying pathology.
The anti-MAG antibody ELISA test by BÜHLMANN is the acknowledged Gold standard by many Neurologists and Laboratories to reliably quantify anti-MAG antibodies in immune-mediated demyelinating neuropathies. Based on highly purified MAG from human brain, the assay is characterized by outstanding sensitivity and specificity. Anti-MAG antibody ELISA may be used as stand-alone test or in combination with BÜHLMANN GanglioCombi™ MAG ELISA to confirm auto-antibodies against MAG.
In addition to the anti-MAG ELISA, the BÜHLMANN anti-SGPG ELISA enhances the chance to detect all IgM-related neuropathies. Anti-SGPG antibodies have a wider spectrum than anti-MAG antibodies – some patients which are anti-SGPG positive are negative for anti-MAG antibodies. Therefore, patients should be tested for both antibodies.
GanglioCombi™ Light ELISA combines on one microplate the three most relevant and frequent gangliosides, GD1b, GQ1b and GM1. The kit contains 3 enzyme labels: IgG/IgM-Mix, IgG and IgM.
Anti-GM1 ELISA allows individual testing of anti-GM1 antibodies of the IgG and/or the IgM isotype. While IgG antibodies are related to Guillain-Barré Syndrome (GBS), IgM antibodies are found in multifocal neuropathy (MMN) and lower motor neuron disease (LMND).